<DOC>
	<DOCNO>NCT02712372</DOCNO>
	<brief_summary>This Phase I , first-in-human ( FIH ) study assess safety , tolerability , pharmacokinetics ( PK ) Pharmacodynamics ( PD ) AZD4831 single multiple ascend dos healthy male subject</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Single Multiple Doses AZD4831 Healthy Male Subjects</brief_title>
	<detailed_description>This Phase I , FIH , randomize , single-blind , placebo-controlled study ass safety , tolerability , pharmacokinetics ( PK ) Pharmacodynamics ( PD ) AZD4831 single ( Part 1 ) multiple ( Part 2 ) ascend dos healthy male subject . The study conduct single study center plan number subject 125 healthy male , age 18 50 year .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Inclusion Criteria Provision sign date , write informed consent study specific procedure . Healthy male subject age 18 50 year , inclusive , suitable vein cannulation repeat venipuncture . Have body mass index ( BMI ) 18 29.9 kg/m2 , inclusive , weigh least 50 kg 100 kg inclusive . Provision sign , write date informed consent optional genetic/biomarker research . Subjects must able read , speak understand German language . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . History presence gastrointestinal ( GI ) , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . Presence infection ( ) ( particularly fungal infection ) , judge investigator . History current thyroid disease . Any clinically significant illness , medical/surgical procedure , trauma within 4 week first administration investigational medicinal product ( IMP ) . Any clinically significant abnormality clinical chemistry , haematology , urinalysis result , judged investigator . Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , antihepatitis B core ( antiHBc ) antibody , hepatitis C antibody human immunodeficiency virus ( HIV ) . Abnormal vital sign Any clinically significant abnormality rhythm , conduction morphology rest ECG clinically significant abnormality 12lead ECG , consider investigator may interfere interpretation QTc interval change , include abnormal STTwave morphology , particularly protocol define primary lead LV hypertrophy . Prolonged QTcF &gt; 450 m shorten QTcF &lt; 340 m family history long QT syndrome . PR ( PQ ) interval shorten &lt; 120 m ( PR &gt; 110 m &lt; 120 m acceptable evidence ventricular preexcitation ) PR ( PQ ) interval prolongation ( &gt; 200 m ) intermittent second ( Wenckebach block asleep exclusive ) third degree AV block , AV dissociation Persistent intermittent complete bundle branch block , incomplete bundle branch block , intraventricular conduction delay QRS &gt; 110 m . Subjects QRS &gt; 110 m &lt; 115 m acceptable evidence , example , ventricular hypertrophy preexcitation . ECG finding suggest metabolic noncardiac condition may confound interpretation serial change ( hypokalemia ) . Known suspected history drug abuse , judge investigator . Current smoker smoke used nicotine product within previous 3 month . History alcohol abuse excessive intake alcohol , judge investigator . Positive screen drug abuse , cotinine ( nicotine ) alcohol screen admission unit first administration IMP . History severe allergy/hypersensitivity ongoing clinically significant allergy/hypersensitivity , judge investigator history hypersensitivity drug similar chemical structure class AZD4831 . Excessive intake caffeine contain drink food ( e.g. , coffee , tea , chocolate ) , judge investigator . Use drug enzyme induce property St John 's Wort within 3 week first administration IMP . Use prescribe nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week first administration IMP long medication long halflife . Plasma donation within 1 month screen blood donation/blood loss &gt; 500 mL 3 month screen . Has receive another new chemical entity ( define compound approve marketing ) within 3 month first administration IMP study . The period exclusion begin 3 month final dose 1 month last visit whichever long . Vulnerable subject , e.g. , keep detention , protect adult guardianship , trusteeship , committed institution governmental juridical order . Involvement Astra Zeneca , PAREXEL study site employee close relative . Judgment investigator subject participate study ongoing recent ( i.e. , screen period ) minor medical complaint may interfere interpretation study data consider unlikely comply study procedure , restriction requirement . Subjects vegans medical dietary restriction . Subjects communicate reliably investigator . Exclusion genetic research : Previous bone marrow transplant . Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AZD4831 oral suspension</keyword>
	<keyword>Healthy male subject</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>